MS-based approaches for studying the pharmacokinetics of protein drugs

“[MS-based quantitative assays] offer interesting characteristics in terms of specificity, precision and robustness, transferability and multiplexing ability … MS utilization could overcome antidrug antibodies interference and deal with questions of metabolism.” The development of new therapeutic proteins and peptides currently involves over 200 companies, sharing a strong growth market of €90 billion in 2010 (vs €25 billion in 2001) [1]. Over 700 therapeutic antibodies, proteins and peptides entered clinical trials between 1980 and 2004, representing half of all medications in the development phase in 2008 [2]. This increasing number of protein drugs highlights the need for the development of quantitative...

To view this content, please register now for access

It's completely free